Baylx Inc.   Report issue

For profit Phase 2
Founded: Irvine CA United States (2017)

Organization Overview

First Clinical Trial
2019
NCT03828344
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Baylx Inc. | Beijing Baylx Biotech Co., Ltd.

Active Ingredients

Drugs in Phase 2 Trials (1)

umbilical cord mesenchymal stem cells (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 1)

Arthritis, Rheumatoid (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 1